Eventide Asset Management DRUG Position
Active7-Fund ConvergenceEventide Asset Management initiated a new position in BRIGHT MINDS BIOSCIENCES INC. (DRUG) in Q4 2025, holding $8.0M worth of shares across 103,013 shares.
DRUG is a convergence signal: 7 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for BMB-101 in 228 days (Nov 30, 2026), making the timing of Eventide's position particularly relevant.
About BRIGHT MINDS BIOSCIENCES INC.
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
Full company profile →Short Interest
7.0%
5.0 days to cover
Frequently Asked Questions
Does Eventide Asset Management own DRUG?
Yes. As of Q4 2025, Eventide Asset Management holds 103,013 shares of BRIGHT MINDS BIOSCIENCES INC. (DRUG) valued at $8.0M. This data comes from their SEC 13F filing.
How many hedge funds own DRUG?
7 specialist biotech hedge funds currently hold DRUG, including Cormorant Asset Management, Driehaus Capital, Perceptive Advisors and 3 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Eventide Asset Management first buy DRUG?
Eventide Asset Management's position in DRUG was first reported in Q4 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Eventide Asset Management's DRUG position increasing or decreasing?
Eventide Asset Management initiated a new position in DRUG in the most recent quarter. This is their first reported holding.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
DRUGCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Eventide Asset ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →